Clinical Trial Search

Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: PFS — 29.8 Months

Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location…

Primary: Number of Patients (%) in Which Sentinel Node(s) Are Detected After Injection of Blue Dye and Tracer in the Ovarian Ligaments. — 21 participants

Primary: Overview of Treatment-emergent Adverse Events (TEAEs) — 3; 13; 11; 2 Participants

Primary: Tolerated Dose — 80 mg/m^2

Primary: Efficacy Patient Level — 26.9 percentage of participants

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants

Primary: Progression-free Survival — 8.85; 8.32 months

Primary: Response Rate — 1; 2; 4 participants

Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Overall Survival — 32 months

Primary: Disease-free Survival — 64; 71; 70 percentage of participants

Primary: Number of Patients With Dose-limiting Toxicities (DLTs) — 0; 0 Participants

Primary: Tumor Response — 23.4 Percentage of participants

Primary: Progression Free Survival — 54 day

Primary: Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment — 386; 478 Days — p=0.655

Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065

Primary: Overall Survival — 2.14; 2.00 years

Primary: Response Rate — 0; 1; 8; 6 Participants

Primary: Safety: Incidence of Post Chemotherapy Surgical Debulking — 15 Participants

Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants

Primary: Best Biochemical Response (Cancer Antigen [CA-125]) — 6; 25; 56; 3 percentage of participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Median Progression-free Survival — 3.2; 4.5 months